arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

INOVIO PHARMACEUTICALS, INC.

INO
$1.24 ▼ -0.05 (-4.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
31 Metrics
Absolute Benchmarks
Price Chart
55
Health
Fair
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, INOVIO PHARMACEUTICALS, INC. shows weak fundamentals, weighed down by Return on Invested Capital. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $101.2M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -336.6% ↘
FCF / Share $-0.22 ↗
Trailing P/E —
Price / Book 23.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-19.68M
— +0.1% —
Operating Margin Operating profit as % of sales
-390.6%
↓ -1735.4% —
FCF / Share Free cash flow per share
$-0.22
↑ +29.2% —
Long-Term Debt Long-term obligations
$62.76M
↑ +3.6% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -360.3% is weak on an absolute basis (target > 10%)

Health Breakdown

Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters